Results 11 to 20 of about 5,286 (232)

ANKRD54 preferentially selects Bruton's Tyrosine Kinase (BTK) from a Human Src-Homology 3 (SH3) domain library. [PDF]

PLoS ONE, 2017
Bruton's Tyrosine Kinase (BTK) is a cytoplasmic protein tyrosine kinase with a fundamental role in B-lymphocyte development and activation. The nucleocytoplasmic shuttling of BTK is specifically modulated by the Ankyrin Repeat Domain 54 (ANKRD54) protein
Manuela O Gustafsson, Dara K Mohammad, Erkko Ylösmäki, Hyunseok Choi, Subhash Shrestha, Qing Wang, Beston F Nore, Kalle Saksela, C I Edvard Smith   +8 more
doaj   +2 more sources

Mechanisms of Resistance to Noncovalent Bruton’s Tyrosine Kinase Inhibitors [PDF]

New England Journal of Medicine, 2022
Covalent (irreversible) Bruton's tyrosine kinase (BTK) inhibitors have transformed the treatment of multiple B-cell cancers, especially chronic lymphocytic leukemia (CLL). However, resistance can arise through multiple mechanisms, including acquired mutations in BTK at residue C481, the binding site of covalent BTK inhibitors.
Eric Wang, Xiaoli Mi, Meghan C. Thompson, Skye Montoya, Ryan Q. Notti, Jumana Afaghani, Benjamin H. Durham, Alex Penson, Matthew T. Witkowski, Sydney X. Lu, Jessie Bourcier, Simon J. Hogg, Caroline Erickson, Dan Cui, Hana Cho, Michael Singer, Tulasigeri M. Totiger, Sana Chaudhry, Mark Geyer, Alvaro Alencar, Adam J. Linley, M. Lia Palomba, Catherine C. Coombs, Jae H. Park, Andrew Zelenetz, Lindsey Roeker, Mary Rosendahl, Donald E. Tsai, Kevin Ebata, Barbara Brandhuber, David M. Hyman, Iannis Aifantis, Anthony Mato, Justin Taylor, Omar Abdel-Wahab   +34 more
openaire   +5 more sources

Autoinhibition of Bruton's tyrosine kinase (Btk) and activation by soluble inositol hexakisphosphate [PDF]

eLife, 2015
Bruton's tyrosine kinase (Btk), a Tec-family tyrosine kinase, is essential for B-cell function. We present crystallographic and biochemical analyses of Btk, which together reveal molecular details of its autoinhibition and activation.
Qi Wang, Erik M Vogan, Laura M Nocka, Connor E Rosen, Julie A Zorn, Stephen C Harrison, John Kuriyan   +6 more
doaj   +2 more sources

Role of Tyrosine Kinase Inhibitors in Indolent and Other Mature B-Cell Neoplasms

Biomarker Insights, 2015
Targeting tyrosine kinases represents a highly specific treatment approach for different malignancies. This also includes non-Hodgkin lymphoma since it is well known that these enzymes are frequently involved in the lymphomagenesis.
Nadine Kutsch, Reinhard Marks, Richard Ratei, Thomas K. Held, Martin Schmidt-Hieber   +4 more
doaj   +2 more sources

Current understanding of tyrosine kinase BMX in inflammation and its inhibitors

Burns & Trauma, 2014
Tec family kinases, which include tyrosine kinase expressed in hepatocellular carcinoma (TEC), Bruton's tyrosine kinase (BTK), interleukin (IL)-2-inducible T-cell kinase (ITK), tyrosine-protein kinase (TXK), and bone marrow tyrosine kinase on chromosome ...
Le Qiu, Fei Wang, Sheng Liu, Xu-Lin Chen
doaj   +2 more sources

Nucleocytoplasmic Shuttling of Bruton's Tyrosine Kinase [PDF]

Journal of Biological Chemistry, 2000
Bruton's tyrosine kinase (Btk), a nonreceptor cytoplasmic tyrosine kinase belonging to the Tec family of kinases, has been shown to be critical for B cell proliferation, differentiation, and signaling. Loss-of-function mutations in the Btk gene lead to X-linked agammaglobulinemia (XLA), a primary immunodeficiency in humans, and the less severe ...
A J, Mohamed, L, Vargas, B F, Nore, C M, Backesjo, B, Christensson, C I, Smith   +5 more
openaire   +2 more sources

Managing toxicities of Bruton tyrosine kinase inhibitors [PDF]

Hematology, 2020
Abstract Inhibition of Bruton’s tyrosine kinase (BTK) has revolutionized the treatment landscape for patients with chronic lymphocytic leukemia (CLL). By targeting this critical kinase in proximal B-cell receptor signaling, BTK inhibitors (BTKis) impair cell proliferation, migration, and activation of NF-κB.
Andrew, Lipsky, Nicole, Lamanna
openaire   +2 more sources

Targeting Bruton’s Tyrosine Kinase in Inflammatory and Autoimmune Pathologies

Frontiers in Cell and Developmental Biology, 2021
Bruton’s tyrosine kinase (BTK) was discovered due to its importance in B cell development, and it has a critical role in signal transduction downstream of the B cell receptor (BCR).
Stefan F. H. Neys, Rudi W. Hendriks, Odilia B. J. Corneth   +2 more
doaj   +1 more source

Effect of Bruton's tyrosine kinase inhibitors on platelet aggregation in patients with acute myocardial infarction [PDF]

, 2019
Aims: Despite widespread use of dual antiplatelet therapy in acute myocardial infarction, there remains a residual risk of morbidity and mortality.
Bhatti, Maria, Bowles, Kristian, Ryding, Alisdair, Rushworth, Stuart, Ayton, Sarah, Geisler, Tobias, Gollop, Nicholas D., Michail, Olga, Flather, Marcus   +8 more
core   +1 more source

Immunomodulating effects of antitumor drugs Bruton tyrosine kinase inhibitors and the possibility of their use in allergic and infectious diseases

Медицинская иммунология, 2023
Bruton's tyrosine kinase (BTK) inhibitors represent a class of drugs that have demonstrated their efficacy and safety in patients with chronic lymphocytic leukemia and non-Hodgkin's lymphomas who were considered refractory to any previously used type of ...
Yu. S. Torshina, N. B. Serebryanaya, T. V. Glazanova, M. A. Mikhalyova, S. V. Voloshin   +4 more
doaj   +1 more source